Business
AstraZeneca likely to run new COVID-19 vaccine trial, CEO says, as questions emerge – Sydney Morning Herald
The company is likely to conduct an additional global vaccine trial after current studies raised questions over its level of protection.
Soriot said he didn’t expect the additional trial to hold up regulatory approvals in the UK and European Union.
Clearance from the US Food and Drug Administration may take longer because the regulator is unlikely to approve the vaccine on the basis of studies conducted elsewhere, especially given the questions over the results, he said. Authorisation in some countries is still expected before the end of the year, he said.
AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing…
-
General20 hours agoOf saints and sinners | The Spectator Australia
-
General20 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News10 hours agoTully Sugar Mill celebrates 100 years of cane harvesting amid floods and cyclones
-
General20 hours agoWhy the nation needs the Nationals to ditch Net Zero